hormonal antineoplastic agents

Summary

Summary: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Top Publications

  1. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
  2. ncbi Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
  3. ncbi Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance
    R A Campbell
    Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
    J Biol Chem 276:9817-24. 2001
  4. ncbi Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
  5. ncbi Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
  6. ncbi Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
  7. ncbi Resistance training and reduction of treatment side effects in prostate cancer patients
    Daniel A Galvão
    School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia
    Med Sci Sports Exerc 38:2045-52. 2006
  8. ncbi Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Ann H Partridge
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1210, Boston, MA 02215, USA
    J Clin Oncol 21:602-6. 2003
  9. ncbi Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
    Andreas Polychronis
    Cancer Research UK Laboratories, Department of Cancer Medicine, Imperial College, London, UK
    Lancet Oncol 6:383-91. 2005
  10. ncbi A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Napoli, Italy
    Clin Cancer Res 11:4741-8. 2005

Research Grants

  1. MIDCAREER INVESTIGATOR AWARD
    Matthew Smith; Fiscal Year: 2007
  2. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
  3. MIDCAREER INVESTIGATOR AWARD
    Matthew Smith; Fiscal Year: 2008
  4. Targeting Androgen -IGF Interactions in Prostate Cancer
    Charles Ryan; Fiscal Year: 2008
  5. Targeting Androgen -IGF Interactions in Prostate Cancer
    Charles Ryan; Fiscal Year: 2007
  6. Mayo Clinic Breast Cancer SPORE
    James Ingle; Fiscal Year: 2007
  7. Mayo Clinic Breast Cancer SPORE
    James Ingle; Fiscal Year: 2008
  8. Tamoxifen biotransformation pathway pharmacogenomics
    MATTHEW PHILIP GOETZ; Fiscal Year: 2010
  9. Tamoxifen biotransformation pathway pharmacogenomics
    Matthew Goetz; Fiscal Year: 2008
  10. Tamoxifen biotransformation pathway pharmacogenomics
    Matthew Goetz; Fiscal Year: 2009

Detail Information

Publications265 found, 100 shown here

  1. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  2. ncbi Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    ..We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance...
  3. ncbi Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance
    R A Campbell
    Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
    J Biol Chem 276:9817-24. 2001
    ..Taken together, these results define a molecular link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERalpha, and inhibition of tamoxifen-induced apoptotic regression...
  4. ncbi Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
    ..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
  5. ncbi Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
    ..To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992...
  6. ncbi Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
    ..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective...
  7. ncbi Resistance training and reduction of treatment side effects in prostate cancer patients
    Daniel A Galvão
    School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia
    Med Sci Sports Exerc 38:2045-52. 2006
    ..To examine the effect of progressive resistance training on muscle function, functional performance, balance, body composition, and muscle thickness in men receiving androgen deprivation for prostate cancer...
  8. ncbi Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Ann H Partridge
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1210, Boston, MA 02215, USA
    J Clin Oncol 21:602-6. 2003
    ..We sought to estimate adherence and predictors of nonadherence in women starting tamoxifen as adjuvant breast cancer therapy...
  9. ncbi Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
    Andreas Polychronis
    Cancer Research UK Laboratories, Department of Cancer Medicine, Imperial College, London, UK
    Lancet Oncol 6:383-91. 2005
    ..Some oestrogen-receptor (ER) positive breast cancers express epidermal growth factor receptor (EGFR), but whether inhibition of EGFR can suppress proliferation of breast cancer cells and ER function is not known...
  10. ncbi A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Napoli, Italy
    Clin Cancer Res 11:4741-8. 2005
    ..Clinical data, however, have been conflicting. We have conducted a meta-analysis on the interaction between the response to endocrine treatment and the overexpression of HER-2 in metastatic breast cancer...
  11. ncbi The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
    Monique J Bijl
    Department of Epidemiology, Erasmus MC, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 118:125-30. 2009
    ..The risk of breast cancer mortality is increased in tamoxifen users with decreased CYP2D6 activity, consistent with the model in which endoxifen formation is dependent on CYP2D6 activity...
  12. ncbi Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
    Athanassios Argiris
    Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 10:1409-20. 2004
    ..This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments...
  13. ncbi Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
    Nael Shoman
    Department of Pathology, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada
    Mod Pathol 18:250-9. 2005
    ..In summary, our results showed a strong association between downregulation of PTEN expression in ER-alpha-positive tumors and failure to tamoxifen treatment...
  14. ncbi Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839)
    Stephen Hiscox
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Redwood Building, King Edward VII Avenue, Cardiff, UK
    Clin Exp Metastasis 21:201-12. 2004
    ..Inhibition of EGFR signalling by gefitinib significantly inhibited cell motility and invasion thus suggesting a role for the EGF receptor in the aggressive phenotype of tamoxifen-resistant breast cancer cells...
  15. ncbi Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor
    J M Knowlden
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, United Kingdom
    Endocrinology 146:4609-18. 2005
    ..This cross-talk between IGF-IR and EGFR is not unique to Tam-R cells because this mechanism is also active in a tamoxifen-resistant T47D-R cell line...
  16. ncbi Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy
    Manfred Kaufmann
    Klinik fur Gynakologie und Geburtshilfe, J W Goethe Universität Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Cancer Res Clin Oncol 131:487-94. 2005
    ..That trial, MA.17, evaluated letrozole as extended adjuvant treatment following standard adjuvant tamoxifen in postmenopausal women with predominantly estrogen receptor--and/or progesterone receptor--positive early breast cancer...
  17. ncbi Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
    Kevin S Hughes
    Avon Comprehensive Breast Evaluation Center, Breast Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital, Division of Surgical Oncology, Boston 02114, USA
    N Engl J Med 351:971-7. 2004
    ..In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy...
  18. ncbi New approaches to the understanding of tamoxifen action and resistance
    L M Berstein
    Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia, PO Box 801416, Charlottesville, VA 22908, USA
    Endocr Relat Cancer 10:267-77. 2003
    ....
  19. ncbi Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer
    Aliza K Fink
    Boston Medical Center, 88 E Newton St, Robinson 2, Boston, MA 02118, USA
    J Clin Oncol 22:3309-15. 2004
    ....
  20. ncbi Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer
    J M Gee
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom
    Int J Cancer 95:247-54. 2001
    ....
  21. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  22. ncbi Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
    J G Klijn
    Dr Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 19:343-53. 2001
    ..Therefore, if a premenopausal woman with advanced breast cancer is thought to be suitable for endocrine treatment, it is proposed that the combination of a LHRH agonist plus tamoxifen be considered as the new standard treatment...
  23. ncbi Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 18:2234-44. 2000
    ....
  24. doi Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study
    Jean Claude Barbare
    Fédération Francophone de Cancérologie Digestive, Association Nationale des Hépato Gastroentérologues des Hôpitaux Généraux, France
    Eur J Cancer 45:1788-97. 2009
    ..A previous study reported a significant survival benefit for octreotide compared with no treatment in patients with advanced hepatocellular carcinoma (HCC). This was investigated further in this multicentre study...
  25. ncbi Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis
    J Seidenfeld
    Blue Cross and Blue Shield Association Technology Evaluation Center, Chicago, Illinois 60601 7680, USA
    Ann Intern Med 132:566-77. 2000
    ..To compare luteinizing hormone-releasing hormone (LHRH) agonists with orchiectomy or diethylstilbestrol, and to compare antiandrogens with any of these three alternatives...
  26. ncbi HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
    D A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:3471-9. 2000
    ..Tamoxifen assignment was not randomized-physician discretion was used for premenopausal and postmenopausal women. Trial protocol then specified assignment to postmenopausal women with ER-positive tumors, although not all took tamoxifen...
  27. ncbi What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
    Belinda Thewes
    Prince of Wales Hospital, Randwick, Sydney, Australia
    Lancet Oncol 6:581-8. 2005
    ..We aimed to quantify the survival gains that premenopausal patients with early-stage breast cancer require to justify the side-effects and inconvenience of adjuvant endocrine treatments...
  28. ncbi Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis
    Cheryl D Bushnell
    Department of Medicine Neurology, Duke University Medical Center, Durham, NC 27710, USA
    Neurology 63:1230-3. 2004
    ..To assess the overall risk of stroke, specifically ischemic stroke, associated with tamoxifen use by performing a meta-analysis of data reported in breast cancer trials...
  29. pmc Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
    J Natl Cancer Inst 100:1380-8. 2008
    ....
  30. ncbi Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    ..To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance...
  31. ncbi Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
    S R Johnston
    Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, England
    Clin Cancer Res 5:251-6. 1999
    ..These observations support the need for further evaluation of these markers in breast tumors as predictors of TAM resistance...
  32. ncbi Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status
    Leena Vehmanen
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    J Clin Oncol 24:675-80. 2006
    ..We conducted a prospective study of the effect of sequential adjuvant therapy with chemotherapy followed by tamoxifen on bone mineral density (BMD) in premenopausal patients...
  33. pmc A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer
    Maia Chanrion
    U868 Institut National de la Sante et de la Recherche Medicale, Tumoral Identity and Plasticity, Cancer Research Center of Montpellier, Universite Montpellier 1, CRLC Val d Aurelle Paul Lamarque, France
    Clin Cancer Res 14:1744-52. 2008
    ..The identification of a molecular signature predicting the relapse of tamoxifen-treated primary breast cancers should help the therapeutic management of estrogen receptor-positive cancers...
  34. ncbi Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
    Anthony Howell
    Christie Hospital and Holt Radium Institute, Manchester, UK
    J Clin Oncol 22:1605-13. 2004
    ....
  35. ncbi MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance
    Natasha Atanaskova
    Department of Pathology, Wayne State University School of Medicine, 540 E Canfield, Detroit, Michigan 48201, USA
    Oncogene 21:4000-8. 2002
    ..Taken together, these data suggest that MAPK/ER cross-talk enhances ERalpha-mediated signaling and accelerates E(2)-dependent tumor growth without diminishing sensitivity to the inhibitory effects of anti-estrogens...
  36. ncbi Androgen deprivation therapy for prostate cancer
    Nima Sharifi
    Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA
    JAMA 294:238-44. 2005
    ..Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease...
  37. ncbi Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
    Susan A Nowell
    Department of Epidemiology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Breast Cancer Res Treat 91:249-58. 2005
    ..These studies indicate that genetic variation in Phase II conjugating enzymes can influence the efficacy of tamoxifen therapy for breast cancer...
  38. ncbi Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
    C Kent Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:353-61. 2003
    ....
  39. ncbi Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
    ....
  40. ncbi Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    A Howell
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    J Clin Oncol 20:3396-403. 2002
    ..To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment...
  41. ncbi Chemotherapy and biotherapy in the treatment of neuroendocrine tumours
    K Oberg
    Department of Endocrine Oncology, Medical Sciences, Internal Medicine, Uppsala University Hospital, Sweden
    Ann Oncol 12:S111-4. 2001
    ..The quality of life has been significantly improved by using the long-acting formulations...
  42. ncbi Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research
    Jose Luis Perez-Gracia
    Clinical Research Department, Eli Lilly and Company, Alcobendas, Madrid, Spain
    Gynecol Oncol 84:201-9. 2002
    ..However, despite the outstanding relevance of hormonal adjuvant therapy in breast cancer and the importance of receptor status as a predictive factor, few trials have addressed these issues in ovarian cancer...
  43. ncbi Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer
    Lisa Gallicchio
    Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 W Redwood Street, Baltimore, MD 21201, USA
    Cancer Lett 211:57-67. 2004
    ..This suggests that diuretic or an arthritis/pain medication may affect TAM metabolism...
  44. ncbi Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer
    Bruce E Hillner
    Department of Internal Medicine, Virginia Commonwealth University, Richmond 23298, USA
    Cancer 101:1311-22. 2004
    ....
  45. ncbi Aromatase inhibitors: future directions
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 95:183-7. 2005
    ....
  46. ncbi Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:5108-16. 2005
    ....
  47. ncbi Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, Texas 77030, USA
    Breast 15:301-12. 2006
    ..The effects of the other AIs on lipid levels are variable, and any correlation with cardiovascular events is currently unknown...
  48. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  49. ncbi Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability
    H Mouridsen
    Novartis Pharma AG, WKL 490 1 04, CH 4057 Basel, Switzerland
    Oncologist 9:489-96. 2004
    ..This subanalysis compares the efficacies of letrozole and tamoxifen as first-line therapy in postmenopausual women with advanced breast cancer according to site of metastatic lesions and Karnofsky Performance Status (KPS)...
  50. ncbi CYP2D6 and tamoxifen: DNA matters in breast cancer
    Janelle M Hoskins
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, 27599, North Carolina, USA
    Nat Rev Cancer 9:576-86. 2009
    ..Here we review the existing data that relate CYP2D6 genotypes to response to tamoxifen and discuss whether the analysis of the CYP2D6 genotype might be an early example of a pharmacogenetic tool for optimizing breast cancer therapy...
  51. ncbi Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways
    Jane Yu
    Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Am J Physiol Lung Cell Mol Physiol 286:L694-700. 2004
    ..The responsiveness of angiomyolipoma cells to estradiol may be related to the underlying reasons that LAM affects primarily women...
  52. ncbi Role of CYP2D6 testing in selection of endocrine therapy for breast cancer
    Justin Stebbing
    Pharmacogenomics 8:1-3. 2007
  53. pmc Meta-analysis of vascular and neoplastic events associated with tamoxifen
    R Scott Braithwaite
    Section of Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicne, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Gen Intern Med 18:937-47. 2003
    ..Our purpose was to estimate the effects of tamoxifen on potentially life-threatening vascular and neoplastic outcomes...
  54. ncbi A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    Beat Thurlimann
    Senology Center of Eastern Switzerland, Kantonsspital, St Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland
    N Engl J Med 353:2747-57. 2005
    ..We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women...
  55. ncbi AKT activation predicts outcome in breast cancer patients treated with tamoxifen
    Tove Kirkegaard
    Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    J Pathol 207:139-46. 2005
    ....
  56. ncbi Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment
    S van der Flier
    Department of Pathology Division of Molecular Biology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 92:120-7. 2000
    ..To investigate its role in clinical breast cancer, we determined the levels of Bcar1/p130Cas protein in a large series of primary breast carcinomas...
  57. ncbi Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
    Y Xu
    Breast Center
    Ann Oncol 19:1423-9. 2008
    ..Human cytochrome P450 2D6 (CYP2D6) genotype may affect the efficacy of tamoxifen treatment in Caucasian women with breast cancer. The most common polymorphism of CYP2D6 in Chinese women is variant 10 (188 C to T)...
  58. ncbi Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
    Christopher S Saigal
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Cancer 110:1493-500. 2007
    ..In the current study, the authors attempted to measure the risk for subsequent cardiovascular morbidity in men with prostate cancer who received ADT...
  59. ncbi CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  60. ncbi Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    A Howell
    Christie Hospital, Manchester, UK
    Lancet 365:60-2. 2005
    ..Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer...
  61. ncbi A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, and University of Milan School of Medicine, Milan, Italy
    J Natl Cancer Inst 95:779-90. 2003
    ....
  62. ncbi Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:85-92. 2006
    ..Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant...
  63. doi Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:289-95. 2008
    ..Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST)...
  64. ncbi Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas
    Raimund Jakesz
    Department of Surgery, Vienna University, Vienna General Hospital, Austria
    J Clin Oncol 20:4621-7. 2002
    ..The purpose of Austrian Breast and Colorectal Cancer Study Group Trial 5 was to compare the efficacy of a combination endocrine treatment with standard chemotherapy...
  65. ncbi Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer
    A Milla-Santos
    The Medical Oncology Service, Nuestra Senyora Del Piltar Hospital, Barcelona, Spain
    Breast Cancer Res Treat 65:119-24. 2001
    ....
  66. ncbi Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors
    M D Radmacher
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 92:48-53. 2000
    ..However, it is unclear whether the effect of tamoxifen in this trial was mainly due to prevention of newly forming tumors or to treatment of occult disease...
  67. ncbi Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors
    G S Takimoto
    Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, Denver 80262, USA
    J Steroid Biochem Mol Biol 69:45-50. 1999
    ..Results should provide new insights into the mechanisms underlying the progression of breast cancer to hormone resistance, and may suggest strategies for delaying or reversing this process...
  68. ncbi p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek University Hospital Rotterdam, The Netherlands
    J Clin Oncol 16:121-7. 1998
    ..We studied whether p53 protein accumulation is a predictive factor for response to tamoxifen treatment in patients with recurrent breast cancer...
  69. ncbi Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial
    Joan Houghton
    Clinical Trials Group, Department of Surgery, Royal Free and University College Medical School, Charles Bell House, London W1W 7EJ, UK
    Lancet 362:95-102. 2003
    ..We aimed to assess the effectiveness of adjuvant radiotherapy and tamoxifen...
  70. ncbi Activation of PI3K/Akt signaling and hormone resistance in breast cancer
    Eriko Tokunaga
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Breast Cancer 13:137-44. 2006
    ..Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy...
  71. ncbi HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer
    M Dowsett
    Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Cancer Res 61:8452-8. 2001
    ..This together with high baseline proliferation is likely to translate to poor clinical response...
  72. ncbi Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer
    Richard R Love
    Departments of Medicine and Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53726, USA
    J Clin Oncol 21:453-7. 2003
    ....
  73. ncbi National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ
    Victor G Vogel
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
    Clin Cancer Res 9:495S-501S. 2003
    ..Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003...
  74. ncbi Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial
    M Andersson
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    Eur J Cancer 35:1659-66. 1999
    ..v., concurrent TAM for 1 year did not improve the outcome. These results do not exclude that receptor positive patients may benefit from adjuvant TAM for longer periods given sequentially to chemotherapy...
  75. pmc Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  76. ncbi Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
    Caroline Holm
    Division of Pathology, Department of Laboratory Medicine, Lund University, Malmo, Sweden
    J Natl Cancer Inst 98:671-80. 2006
    ..Here we studied associations between Pak1 expression and subcellular localization in tumor cells and tamoxifen resistance...
  77. ncbi Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, USA
    J Clin Oncol 24:4448-56. 2006
    ..We assessed whether androgen deprivation therapy is associated with an increased incidence of diabetes and cardiovascular disease...
  78. pmc Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
    Werner Schroth
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    JAMA 302:1429-36. 2009
    ..The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme...
  79. ncbi Endocrine and immune responses to resistance training in prostate cancer patients
    D A Galvão
    Vario Health Institute, Edith Cowan University, Joondalup, Western Australia, Australia
    Prostate Cancer Prostatic Dis 11:160-5. 2008
    ..05) following acute exercise. Resistance exercise does not appear to compromise testosterone suppression, and acute elevations in serum GH and DHEA may partly underlie improvements observed in physical function...
  80. pmc Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study
    Raman Vinayagam
    Clatterbridge Cancer Research Trust, J K Douglas Laboratories, Clatterbridge Hospital, Bebington, Wirral, Merseyside, UK
    BMC Cancer 7:131. 2007
    ..We therefore now assess ERbeta2 protein by immunostaining and mRNA by quantitative RT-PCR in relation to treatment outcome...
  81. ncbi Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 16:1569-83. 2005
    ....
  82. ncbi Selective estrogen-receptor modulators and antihormonal resistance in breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 25:5815-24. 2007
    ..This will allow the precise treatment of diseases that was previously considered impossible...
  83. ncbi Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture
    Djuana M E Harvell
    Department of Medicine, University of Colorado Health Sciences Center at Fitzsimons, Aurora, 80045, USA
    Endocrinology 147:700-13. 2006
    ..This indicates the extent to which gene expression profiles are uniquely dependent on hormone-treatment times and the cellular microenvironment...
  84. ncbi Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients
    O Markovitch
    Department of Obstetrics and Gynecology, Meir Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba 44281, Israel
    Breast Cancer Res Treat 101:185-90. 2007
    ..There is a necessity to find out if aromatase inhibitors can also decrease endometrial thickness in patients previously treated with long-term tamoxifen treatment...
  85. ncbi Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
    Lesley J Fallowfield
    Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, Falmer, United Kingdom
    J Clin Oncol 24:910-7. 2006
    ..To compare and describe the quality of life (QOL) of women allocated to tamoxifen or exemestane within the Intergroup Exemestane Study (IES)...
  86. ncbi First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II, University of Naples, Italy
    Clin Endocrinol (Oxf) 64:342-51. 2006
    ..The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor...
  87. ncbi Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma
    Enrique Castellón
    Physiology and Biophysics Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
    Cancer Invest 24:261-8. 2006
    ..These differences with pituitary receptors may be explained by differences in affinity, transduction mechanism and molecular context in prostatic tissue...
  88. ncbi Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study
    Patrick Neven
    Multidisciplinary Breast Centre and Gynaecological Oncology, UZ KULeuven, Leuven, Belgium
    Breast Cancer Res Treat 109:59-65. 2008
    ....
  89. ncbi Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth
    D J Britton
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
    Breast Cancer Res Treat 96:131-46. 2006
    ....
  90. ncbi Adherence to tamoxifen over the five-year course
    Timothy L Lash
    Department of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA
    Breast Cancer Res Treat 99:215-20. 2006
    ..To estimate the proportion of older women who fail to complete 5 years of tamoxifen therapy and to identify predictors of non-adherence...
  91. pmc Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
    K Jirstrom
    Division of Pathology Department of Laboratory Medicine, Lund University, Malmo University Hospital, SE 205 02, Malmo, Sweden
    J Clin Pathol 58:1135-42. 2005
    ..These parameters are the net result of combinations of genetic alterations effecting tumour behaviour and could potentially reflect subtypes that respond differently to endocrine treatment...
  92. ncbi Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 93:S11-8. 2005
    ....
  93. ncbi Epigenetic information and estrogen receptor alpha expression in breast cancer
    Laura Giacinti
    Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, Pennsylvania 19122 6009, USA
    Oncologist 11:1-8. 2006
    ..This paper reviews the current understanding of the role of epigenetic information in the development of cancer and its significance in breast cancer as predictive markers of ER status and as new targets of anticancer therapy...
  94. ncbi Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial
    Francesco Boccardo
    National Cancer Research Institute, 16132 Genoa, Italy
    J Clin Oncol 23:5138-47. 2005
    ..Moreover, many women relapse during or after tamoxifen therapy because of the development of resistance. Therefore new approaches are required...
  95. ncbi Multiple targeting by the antitumor drug tamoxifen: a structure-activity study
    Philippe de Medina
    Département Innovation thérapeutique et Oncologie Moléculaire, Centre de Physiopathologie de Toulouse Purpan, INSERM U 563, C P T P, Institut Claudius Regaud, 20 24 rue du Pont saint Pierre, 31052 Toulouse Cedex, France
    Curr Med Chem Anticancer Agents 4:491-508. 2004
    ..These data provide a useful guide for the conception of selective ligands of ERs, AEBS, PKC, CaM or ACAT based on the chemical structure of tamoxifen...
  96. ncbi Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
    L Mauriac
    Institut Bergonie, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud Ouest, 229, cours de l Argonne, 33076, Bordeaux, France
    Eur J Cancer 39:1228-33. 2003
    ..Fulvestrant is at least as effective as anastrozole, providing a valuable treatment option for advanced breast cancer in postmenopausal women with visceral metastases who have failed on prior endocrine therapy...
  97. ncbi Radical prostatectomy versus watchful waiting in early prostate cancer
    Anna Bill-Axelson
    Department of Urology, University Hospital, Uppsala, Sweden
    N Engl J Med 352:1977-84. 2005
    ..In 2002, we reported the initial results of a trial comparing radical prostatectomy with watchful waiting in the management of early prostate cancer. After three more years of follow-up, we report estimated 10-year results...
  98. ncbi Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells
    Nicola J Jordan
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK
    Breast Cancer Res Treat 87:167-80. 2004
    ..Increased Akt1 activation may contribute to the aggressive phenotype of tamoxifen resistant ER (oestrogen receptor) positive breast cancers...
  99. ncbi Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
    Bernard Fisher
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet 364:858-68. 2004
    ..We present long-term findings from those trials and relate them to age, menopausal status, and tumour oestrogen-receptor concentrations. We also discuss the extent of progress made in the treatment of such patients...
  100. ncbi Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer
    Daniel A Galvão
    Vario Health Institute, Edith Cowan University, Joondalup, Australia
    BJU Int 102:44-7. 2008
    ..To assess the effects of androgen deprivation therapy (ADT) on whole-body and regional muscle, fat and bone mass in men with prostate cancer without metastatic bone disease...
  101. pmc Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
    M Stendahl
    Division of Pathology, Department of Laboratory Medicine, Lund University, , , Sweden
    Br J Cancer 90:1942-8. 2004
    ..Our results suggest that cyclin D1 overexpression predicts for tamoxifen treatment resistance in breast cancer, which is line with recent experimental data using breast cancer cell lines and overexpression systems...

Research Grants150 found, 100 shown here

  1. MIDCAREER INVESTIGATOR AWARD
    Matthew Smith; Fiscal Year: 2007
    ..In addition, this research program may help decrease the burden of cancer treatment for prostate cancer survivors. ..
  2. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
    ..In addition, this project will provide important insights into the relative contributions of testosterone and estrogen in bone metabolism, and maintenance of muscle size and strength in older men. ..
  3. MIDCAREER INVESTIGATOR AWARD
    Matthew Smith; Fiscal Year: 2008
    ..In addition, this research program may help decrease the burden of cancer treatment for prostate cancer survivors. ..
  4. Targeting Androgen -IGF Interactions in Prostate Cancer
    Charles Ryan; Fiscal Year: 2008
    ....
  5. Targeting Androgen -IGF Interactions in Prostate Cancer
    Charles Ryan; Fiscal Year: 2007
    ....
  6. Mayo Clinic Breast Cancer SPORE
    James Ingle; Fiscal Year: 2007
    ....
  7. Mayo Clinic Breast Cancer SPORE
    James Ingle; Fiscal Year: 2008
    ....
  8. Tamoxifen biotransformation pathway pharmacogenomics
    MATTHEW PHILIP GOETZ; Fiscal Year: 2010
    ....
  9. Tamoxifen biotransformation pathway pharmacogenomics
    Matthew Goetz; Fiscal Year: 2008
    ....
  10. Tamoxifen biotransformation pathway pharmacogenomics
    Matthew Goetz; Fiscal Year: 2009
    ....
  11. Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
    Timothy Lash; Fiscal Year: 2007
    ..Understanding the modification of tamoxifen effectiveness by genetic polymorphisms or drug interactions will help patients and physicians to make fully informed decisions about hormone therapy. ..
  12. Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial
    Edith Perez; Fiscal Year: 2008
    ..Our study proposes biomarker tissue correlative studies to help identify those patients most likely to benefit from this treatment. ..
  13. Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial
    Edith Perez; Fiscal Year: 2009
    ..Our study proposes biomarker tissue correlative studies to help identify those patients most likely to benefit from this treatment. ..
  14. Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
    Timothy Lash; Fiscal Year: 2008
    ..Understanding the modification of tamoxifen effectiveness by genetic polymorphisms or drug interactions will help patients and physicians to make fully informed decisions about hormone therapy. ..
  15. SMOKING & GENETIC INTERACTION IN BREAST CANCER ETIOLOGY
    Timothy Lash; Fiscal Year: 2004
    ..The second study would collect buccal swabs from participants in the study of adjuvant tamoxifen therapy (Dr. Silliman PI). A similar analytic plan would be conducted, but with a case-only design. ..
  16. Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial
    MONICA MADDEN REINHOLZ; Fiscal Year: 2010
    ..Our study proposes biomarker tissue correlative studies to help identify those patients most likely to benefit from this treatment. ..
  17. Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
    Timothy Lash; Fiscal Year: 2006
    ..Understanding the modification of tamoxifen effectiveness by genetic polymorphisms or drug interactions will help patients and physicians to make fully informed decisions about hormone therapy. ..
  18. Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
    Timothy Lash; Fiscal Year: 2009
    ..Understanding the modification of tamoxifen effectiveness by genetic polymorphisms or drug interactions will help patients and physicians to make fully informed decisions about hormone therapy. ..
  19. SPORE IN BREAST CANCER
    SARA SUKUMAR; Fiscal Year: 2008
    ....
  20. DNA METHYLATION AS A DETERMINANT OF BREAST CANCER
    Nancy Davidson; Fiscal Year: 2002
    ..Taken together these studies should provide new insights into the biology of hormone resistance and possible novel therapeutic targets. ..
  21. SPORE IN BREAST CANCER
    Nancy Davidson; Fiscal Year: 2007
    ....
  22. Predicting Non-Sentinel Node Metastasis in Breast Cancer Patients
    Anees Chagpar; Fiscal Year: 2008
    ....
  23. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2004
    ..abstract_text> ..
  24. VISUAL ADAPTATION LIMITS AND AGE-RELATED DISEASE
    Alvin Eisner; Fiscal Year: 2002
    ....
  25. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2006
    ..abstract_text> ..
  26. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2004
    ..abstract_text> ..
  27. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2007
    ..abstract_text> ..
  28. Louisville Breast Cancer Update
    Anees Chagpar; Fiscal Year: 2007
    ..This annual event is the only one of its kind in Kentucky, and provides an important resource for education of clinicians, scientists and advocates. ..
  29. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2003
    ..abstract_text> ..
  30. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2003
    ..abstract_text> ..
  31. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2006
    ..abstract_text> ..
  32. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2005
    ..abstract_text> ..
  33. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2005
    ..abstract_text> ..
  34. Resveratrol, Carbohydrate Restriction and Prostate Cancer Progression
    Salvatore V Pizzo; Fiscal Year: 2010
    ....
  35. SFSU/UCSF Comprehensive Cancer Partnership Program
    Mack Roach; Fiscal Year: 2007
    ..abstract_text> ..
  36. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew J Ellis; Fiscal Year: 2010
    ....
  37. VISUAL ADAPTATION LIMITS AND AGE-RELATED DISEASE
    Alvin Eisner; Fiscal Year: 1999
    ....
  38. VISUAL ADAPTATION LIMITS AND AGE-RELATED DISEASE
    Alvin Eisner; Fiscal Year: 2001
    ....
  39. SFSU/UCSF Comprehensive Cancer Partnership Program
    Mack Roach; Fiscal Year: 2008
    ..abstract_text> ..
  40. Resveratrol, Carbohydrate Restriction and Prostate Cancer Progression
    Stephen Freedland; Fiscal Year: 2009
    ....
  41. Louisville Breast Cancer Update
    Anees Chagpar; Fiscal Year: 2008
    ..This annual event is the only one of its kind in Kentucky, and provides an important resource for education of clinicians, scientists and advocates. ..
  42. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2009
    ....
  43. VISUAL ADAPTATION LIMITS AND AGE-RELATED DISEASE
    Alvin Eisner; Fiscal Year: 2000
    ....
  44. NEW APPROACHES TO EVALUATION AND TREATMENT OF ACROMEGALY
    Pamela Freda; Fiscal Year: 2006
    ..abstract_text> ..
  45. UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
    Philip Lazarus; Fiscal Year: 2004
    ..These studies may provide potentially important genetic biomarkers which may reflect upon an individual's risk for oral and potentially other tobacco-related cancers. ..
  46. Using Message Framing to Promote Physical Activity in Colorectal Cancer Survivors
    Lee Jones; Fiscal Year: 2008
    ..The study also explores for whom and why these messages may be effective. ..
  47. ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
    Angela Brodie; Fiscal Year: 2005
    ..Determine effective doses, scheduling, and route of administration and b. Compare the effect of lead inhibitors and castration on apoptosis to identify the best compound. ..
  48. STUDY OF OSTEOPOROTIC FRACTURES
    Steven Cummings; Fiscal Year: 2005
    ....
  49. ROLE OF THE CELL CYCLE IN HYPERSENSITIVITY TO ESTRADIOL
    Richard Santen; Fiscal Year: 2003
    ..abstract_text> ..
  50. Analysis of 5'UTR-Mediated Regulation of p53 Expression
    Philip Lazarus; Fiscal Year: 2002
    ..abstract_text> ..
  51. ROLE OF THE CELL CYCLE IN HYPERSENSITIVITY TO ESTRADIOL
    Richard Santen; Fiscal Year: 2002
    ..abstract_text> ..
  52. In Vivo Efficacy of Multi-Targeted Androgen Inhibition as Prostate Cancer Therapy
    Elahe Mostaghel; Fiscal Year: 2008
    ....
  53. ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
    Angela Brodie; Fiscal Year: 2000
    ..These studies should enable us to select the most effective inhibitors by the end of the grant period, that can then be advanced to phase I trials. ..
  54. NEW APPROACHES TO EVALUATION AND TREATMENT OF ACROMEGALY
    Pamela Freda; Fiscal Year: 2007
    ..abstract_text> ..
  55. ITEM BANKING AND CAT FOR QUALITY OF LIFE OUTCOMES
    David Cella; Fiscal Year: 2000
    ..abstract_text> ..
  56. STUDY OF OSTEOPOROTIC FRACTURES
    Steven Cummings; Fiscal Year: 2002
    ....
  57. UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
    Philip Lazarus; Fiscal Year: 2000
    ..These studies may provide potentially important genetic biomarkers which may reflect upon an individual's risk for oral and potentially other tobacco-related cancers. ..
  58. TAMOXIFEN & BREAST CANCER--ACCEPTANCE/COST EFFECTIVENESS
    Joy Melnikow; Fiscal Year: 2000
    ..abstract_text> ..
  59. NEW APPROACHES TO EVALUATION AND TREATMENT OF ACROMEGALY
    Pamela Freda; Fiscal Year: 2003
    ..My sponsor, Dr. Wardlaw, continues to be committed to providing me with the guidance I need to pursue my research plans and to facilitate my transition to independent investigator. ..
  60. Phase III Trial of Exercise Training in Postsurgical Lung Cancer
    Lee Jones; Fiscal Year: 2009
    ..Despite its importance, effective interventions to improve exercise capacity among lung cancer patients are not available. ..
  61. Analysis of 5'UTR-Mediated Regulation of p53 Expression
    Philip Lazarus; Fiscal Year: 2006
    ..abstract_text> ..
  62. Analysis of 5'UTR-Mediated Regulation of p53 Expression
    Philip Lazarus; Fiscal Year: 2004
    ..abstract_text> ..
  63. UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
    Philip Lazarus; Fiscal Year: 2007
    ..These studies should significantly impact on the field of cancer genetics and epidemiology as they will enable us to better assess the role of variation in glucuronidation pathways and cancer induction. ..
  64. UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
    Philip Lazarus; Fiscal Year: 2009
    ..These studies should significantly impact on the field of cancer genetics and epidemiology as they will enable us to better assess the role of variation in glucuronidation pathways and cancer induction. ..
  65. Analysis of 5'UTR-Mediated Regulation of p53 Expression
    Philip Lazarus; Fiscal Year: 2005
    ..abstract_text> ..
  66. UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
    Philip Lazarus; Fiscal Year: 2001
    ..These studies may provide potentially important genetic biomarkers which may reflect upon an individual's risk for oral and potentially other tobacco-related cancers. ..
  67. UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
    Philip Lazarus; Fiscal Year: 2002
    ..These studies may provide potentially important genetic biomarkers which may reflect upon an individual's risk for oral and potentially other tobacco-related cancers. ..
  68. TOBACCO AND CANCER RISK--DOSE, METABOLISM AND GENETICS
    Philip Lazarus; Fiscal Year: 2004
    ..abstract_text> ..
  69. UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
    Philip Lazarus; Fiscal Year: 2003
    ..These studies may provide potentially important genetic biomarkers which may reflect upon an individual's risk for oral and potentially other tobacco-related cancers. ..
  70. ADJUVANT HORMONAL THERAPY IN VIETNAMESE BREAST CANCER
    Richard Love; Fiscal Year: 2001
    ....
  71. Prevention of prostate cancer by Lipitor, Celebrex and voluntary exercise
    Xi Zheng; Fiscal Year: 2008
    ..We anticipate that the anti-carcinogenesis effect of voluntary exercise in combination with Lipitor and Celebrex will have great utility in human cancer prevention. ..
  72. RENIN ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF ADPKD
    Vicente Torres; Fiscal Year: 1992
    ..The results of these studies will augment the understanding of the pathogenesis of cyst formation and hypertension in ADPKD and are likely to have a significant impact on the treatment of this disease...
  73. AROMATASE INHIBITORS FOR CONTROL OF BREAST CANCER
    Angela Brodie; Fiscal Year: 1980
    ..We also propose to apply aromatase inhibitors to studying the interrelationships of estrogen with other hormones and their effects on steroid hormone plasma and receptor levels. ..
  74. ADJUVANT HORMONAL THERAPY IN VIETNAMESE BREAST CANCER
    Richard Love; Fiscal Year: 2000
    ....
  75. Fractures, Heart Disease, and Stroke on Aromatase Inhibitors
    Nancy Keating; Fiscal Year: 2008
    ....
  76. ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
    Angela Brodie; Fiscal Year: 2000
    ..These studies should enable us to select the most effective inhibitors by the end of the grant period, that can then be advanced to phase I trials. ..
  77. DCIS--MAMMOGRAPHIC FEATURES AND PROGNOSIS
    Laurel Habel; Fiscal Year: 2001
    ..abstract_text> ..
  78. ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
    Angela Brodie; Fiscal Year: 2001
    ..These studies should enable us to select the most effective inhibitors by the end of the grant period, that can then be advanced to phase I trials. ..
  79. Soy Food and Coronary Heart Disease in Women
    Xiao Ou Shu; Fiscal Year: 2008
    ....
  80. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009
    ..This knowledge will provide an evidence base for future pre-prescription genotyping for accurate warfarin dosing and facilitate its use in qualifying patients. ..
  81. Pharmaceuticals and Cancer
    Laurel Habel; Fiscal Year: 2009
    ..Our program provides a valuable mechanism to identify early signs of possible carcinogenic effects of the most commonly used medications or reassurance as to their safety in this regard. ..
  82. Cohort Study of Cancer-Inhibitory Dietary Factors in Men
    Xiao Ou Shu; Fiscal Year: 2010
    ..The results from this study may guide new strategies in the primary prevention of common cancers in both Western and Asian men. ..
  83. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009
    ..This knowledge will provide an evidence base for future pre-prescription genotyping for accurate warfarin dosing and facilitate its use in qualifying patients. ..
  84. Genetic and Environmental Determinants of Warfarin Response
    Nita Limdi; Fiscal Year: 2009
    ..This knowledge will provide an evidence base for future pre-prescription genotyping for accurate warfarin dosing and facilitate its use in qualifying patients. ..
  85. Breast Cancer Survival: Lifestyle and Genetic Determinants
    Xiao Ou Shu; Fiscal Year: 2009
    ..The proposed study, built on successfully implemented cohort studies, will be extremely timely and cost-efficient. ..